CARDIOPROTECTION WITH DEXRAZOXANE FOR DOXORUBICIN-CONTAINING THERAPY IN ADVANCED BREAST-CANCER

Purpose: To determine the cardioprotective effect of dexrazoxane (DZR) used in a doxorubicin-based combination therapy in advanced breast ca ncer. Patient and Methods: Between November 1988 and January 1991, 534 patient with advanced breast cancer were randomized to two multicente r, double-blind studies (088001 and 088006). patients received fluorou racil, doxorubicin, and cyclophosphamide (FAC) with either DZR (DZR-to -doxorubicin ratio, 10:1) or placebo (PLA) every 3 weeks and were moni tored with serial multiple-gated acquisition (MUGA) scans. Results: Th e hazards ratio (HR) of PLA to DZR for a cardiac event, which was pred efined ejection fraction changes or congestive heart failure (CHF), wa s 2.63 (95% confidence interval [CI], 1.61 to 4.27; P < .001) for 0880 01 and 2.00 (95% CI, 1.01 to 3.96; P = .038) for 088006, The objective response rates for 888001 were 46.8% for DZR and 60.5% for PLA, a dif ference of 14% (95% CI, -25% to -2%; P = .019), and for 088006 were 53 .7% for DZR and 49.3% far PLA, a difference of 4% (95% CI, -13% to 22% ; P = .63). Time to progression and survival were not significantly di fferent between treatment arms in either study. Toxicities on the DZR arms included Bower granulocyte and platelet counts at nadir (P = .009 and P = .004, respectively) and more pain on injection (P = .001), wi th no difference in the rates of fever, infection, or hemorrhage. Conc lusion: DZR had a significant cardioprotective effect as measured by n oninvasive testing and clinical CHF. One of the two studies (088001) s howed a lower response rate with DZR, but time to progression and surv ival were not significantly different, DZR is the first agent shown to reduce cardiotoxicity from doxorubicin. (C) 1997 by American Society of Clinical Oncology.